First AD

Second AD

BTK-Targeted Therapy for CLL

Acalabrutinib Versus Ibrutinib for CLL

Acalabrutinib Treatment Considerations in CLL

Selecting Frontline Therapy for CLL

MRD and 11q Deletions in CLL

BTK Inhibitors for Elderly Patients With CLL

Long-Term Experience With BTK Inhibitors for CLL

Combination Therapies With BTK Targeted Therapy in CLL

BTK Inhibition in CLL: Real-World Data

Resistance to BTK Targeted Therapy in CLL

Treating CLL With BTK Inhibition: Next Steps

Precision Medicine

Chronic Lymphocytic Leukemia

Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection. 

Expanding Options for Treatment of CLL Using BTK Inhibitors

Expanding Options for Treatment of CLL Using BTK Inhibitors

Targeted Oncology